# Replimune Group Inc. (REPL) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $20.65, market value $2.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Replimune Group Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 9.6×**. The shares trade at 9.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -12.6%** (5-yr avg -24.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -188.9%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -10.1%**. Earnings per share fell 10.1%.

## Financial health
- **Debt to equity: 0.50**. Debt is 0.50 times equity, moderate leverage.
- **Current ratio: 4.79** (quick 4.79). Current assets cover the next year's liabilities 4.79 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Replimune Group Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (6 analysts). 6 analysts cover Replimune Group Inc.; the consensus is buy, with an average price target of $23.33 (+13% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 100.3%** (YTD 100.5%, 3-mo 63.6%). The shares are up 100.3% over twelve months including dividends.
- **From 52-week high: -2.9%** (1276.7% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 80**. An RSI of 80 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 1.63** (volatility 188%). Beta of 1.63 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=REPL · Page: https://foliofundamentals.com/stocks/repl

Not investment advice.